ANGO logo

ANGO
Angiodynamic Inc

1,032
Mkt Cap
$495.22M
Volume
308,387.00
52W High
$13.50
52W Low
$6.63
PE Ratio
-15.36
ANGO Fundamentals
Price
$12.02
Prev Close
$11.73
Open
$11.73
50D MA
$11.28
Beta
0.94
Avg. Volume
641,926.35
EPS (Annual)
-$0.8321
P/B
2.79
Rev/Employee
$433,330.37
Loading...
Loading...
News
all
press releases
AngioDynamics to Participate in the UBS Global Healthcare Conference
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient...
Business Wire·13d ago
News Placeholder
More News
News Placeholder
AngioDynamics NanoKnife System Named to TIMEs 2025 Best Inventions List
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient...
Business Wire·27d ago
News Placeholder
ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves
AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.
Zacks·1mo ago
News Placeholder
AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
Zacks·2mo ago
News Placeholder
Nutriband Inc. (NTRB) Reports Q2 Loss, Lags Revenue Estimates
Nutriband (NTRB) delivered earnings and revenue surprises of -1,147.06% and -11.77%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Why Is Penumbra (PEN) Up 5% Since Last Earnings Report?
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
ANGO benefits from NanoKnife, clinical milestones, and a balanced portfolio despite tariff headwinds.
Zacks·3mo ago
News Placeholder
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
Zacks·4mo ago
News Placeholder
AngioDynamics (ANGO) Reports Q4 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +76.92% and +7.52%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest ANGO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.